Member Info for crumbs

MM control the spread so pull sp ask right down and make it all look very red hoping to spook many to sell and attract many to buy they get paid both ways .... shame on any who panic sold but you learn

Vinny needs to straighten things out with some clear media here as the idea of the demerger was to add value not lose it lol .... bit of an Ole Solskjear moment this

We do need money though and huge support to get into a ph3 and then on success to gain approval and distribution all things CEPI can do ... So I think Scancell would accept their money if they were chosen but only if there is nothing certain coming from the likes of Merck or Roche etc....And also only if that route is one Scancell have put in for (likely) and of course most vital that CEPI have chosen Covidity lol..... there is always to my mind politics involved in CEPIs choices ... I'd like to think Covidity being a UK vax should not hinder in their decision... also by now there may well be some form of trial data even if it is only - well tolerated ie no adverse side effects so far.

What we can say is CEPI are about to announce funding for their chosen next-gen vaxs from their $200 million call.

Covidity does look like a potential candidate there are going to be plenty of others in the race but at least we are now in that race and data will still rule....

In the beginning I was all for the CEPI route others (nana) were not ... the whole 'for cost' meaning no profit for Scancell being an issue... one I did not then mind as to me the pluses far out weighed the minuses .... A fully backed all the way Covidity with manufacture and distribution covered at no cost to Scancell the exposure for Scancell and value-added to ImmunoBody/Avidimab with potential of attractive deals increased... etc oh and the keeping of IP

Now though I'm not so sure ... as the race has gone on we have seen some very big winners and my preferred route would be a BioNTech one I'd like some of that mRNA success and profit ... so that would mean a pharma partner... the issue is though it is a crowded race time is not on anyone side and we need to get over the finish line if no pharma is committing but CEPI are then we have to go that route we already experienced what happened with SCIB1 waiting on an interested partner....

Still the main thing... Covidity is now in the race and data is coming :) ..... plenty of future fun for all lol

Getting to the finals of the GC was not disappointing it was the then not getting over the funding line for a modi3 blueprint project funding but with Covidity unlike that modi3 we have a product actually in a real trial so really if the vaxs announced by CEPI does not include Covidity, of course, people can ask why not Covidity but they should not be disappointed as my point was we were always in the race to lose GC we have no idea whatsoever if Covidity was presented to CEPI for their $200 million call .... Of course if that is the case and is chosen.... happy days we know Covidity will secure the backing to get into a ph3 and beyond etc... It will still all depend on the data though... So as long as that is great I won't be disappointed ...yet lol

It is part of their $200 millon call where indeed they did ask for applicants ... those are the vaxs that are about to be announced I do think Covidity fits their criteria and indeed the ImmunoBody platform offers great broader potential to them we just have no idea if Scancell applied infact even if vaxs are announced and Covidity isn't one that can mean either they applied and failed or they did not apply lol.... so the GC element just does not apply... what we do know for a fact is getting Covidity into a ph3 will need at partner of which CEPI could fulfil .... anyways looking forward to the data flow and of course on that being great on getting that ph3 by whatever partnering option/s .... Covid vaxs are the absolute pharma blockbusters of our era so though CEPI is a very viable path it is not particularly our most profitable one... anyways main thing is getting it all the way either route would I think have a very positive sp affect! :) and all those labs sing British unicorn biotech to me! (£1billion mcap)

We knew we were in the Grand Challenge finals whereas we have no idea if we are in the CEPI call ... we can guess from RGs retweeting and then not retweeting of CEPI tweets that we possibly did present Covidity to them and it is up to CEPI to decide I...anyways we will all find out if that is the route to ph3 scancell are taking... there are other possibly much more lucrative for Scancell routes and I have no doubts those avenues are being ventured too but it will all hang on the data which is, at last, being generated the facilities expansion and increase in capabilities makes me confident something is coming with money attached just not sure what lol.... still it will be interesting to see what vaxs CEPI are about to back...

I suppose scancell are constantly having to sell Covidity to third parties and of course, the real human data is the gold and that mine is now being dug hurrah but all these lab experiments will be significant to getting interest from potential partners ... no partner no ph3

Well, we know the science never sleeps here and what we know is often many months behind what has or is going on.... so probably all kinds of lab experiments going on getting interesting results... I'm just so happy there is now a scancell product inside at least one 'subject' again...... the fact Avidimab is in it too ... just massive potential... looking forwards to data and of course hope the trial has no recruitment issues.... I know of people over here who the main reason they have yet to have a vax is due to needle phobia... so again whole pharmajet angle so significant....

It was in the trial Approval RNS Ivy

'SCOV1 and SCOV2, targeting the original and variant SARS-CoV-2 viruses, respectively, are based on a modification of Scancell's ImmunoBody® DNA vaccine technology and have a dual mechanism of action to induce high avidity T-cell immune responses against both the N and S viral antigens. Targeting the receptor-binding domain (RBD) of the S antigen, the vaccines also elicit high titre virus-neutralising antibodies (VNAbs) that cross-react against a range of Variants of Concern (VoC), including the new Delta variant.'

I was thinking the timing is more to do with the trial taking place in S.A having said that the time there is only 2 hours ahead... so hmm have to see in the morning lol... but scancell are finally in the Covid vaccine race yes there are a lot of competitors some way ahead and backed by massive money but the race is far from over and now well Covidity gets its chance to show it can be a winner and we all know what would come with that kind of data.... looking forwards to modi1 trial beginning too now :) oh and SCIB1 combo finally finding a patient or subject to dose would be have a drink worthy news! :)

Has fired and we are off!! Well done team Scancell and of course our favourite 'subject' :) all down to the tech and the science behind it now.... 'unrivalled' well time to prove that up :)

Err whoever said there was no competition out there? there is lots of it and there will be lots of next-gen vaxs too I'm not sure why you are writing to scancell about it .... We are in the mix our vax will get to prove itself or otherwise and it has certain advantages over many but it will all be down to data and it getting backed through a ph3.... Trial is registered on the clinical trial site patients will be dosed in due time .... relax lol

Well it will be a % chance Tuesday

Looks like a potential modi 2 target yeah
https://www.scancell.co.uk/modi-2

'ß-catenin is a proto-oncogene and mutations are commonly found in a variety of cancers, including primary hepatocellular carcinoma, colorectal cancer, ovarian carcinoma, breast cancer, lung cancer and glioblastoma.'

It being Sunday and all it could be fun to speculate on if and it is only an if CEPI has indeed taken an interest in getting involved with Covidity as part of their $200 funding ... I wonder would such news be 'sp breakout' worthy I reckon it probably would though to be honest now I'd rather great data and a pharma deal on that but certainly if CEPI are offering to get involved now and pharma are looking uncertain it is better to go with CEPI .... guess we could find out this coming week or not! :) BTW would not think scancell would get anything like the full $200 million straight up but possibly $20 million for starters and the surety of backing all the way through ph3 and commercial on data success...

Considering RG went silent on retweeting CEPI articles after a flurry many months ago this is indeed interesting... what it means though I dunno lol.... At the time of going silent on CEPI I thought it could well have meant they were approached and talks were taking place.... therefore now either those talks are over and something or nothing is coming from them or RG just did not like all the CEPI posts between then and now :).... Anyways a good article

I think that is more to do with that is the officially recognised way to register clinical trials and is not about running a trial in the US ...

That was pretty good but I think Lindy would have given a better 'insight lol
Ball is well in at the BBC though which is positive as the trial progresses and hopefully produces very compelling data...

That was pretty good but I think Lindy would have given a better 'insight lol
Ball is well in at the BBC though which is positive as the trial progresses and hopefully produces very compelling data...